JP2015503560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503560A5 JP2015503560A5 JP2014550335A JP2014550335A JP2015503560A5 JP 2015503560 A5 JP2015503560 A5 JP 2015503560A5 JP 2014550335 A JP2014550335 A JP 2014550335A JP 2014550335 A JP2014550335 A JP 2014550335A JP 2015503560 A5 JP2015503560 A5 JP 2015503560A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- solid dispersion
- hcv
- solid
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 11
- 239000007962 solid dispersion Substances 0.000 claims 8
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000006104 solid solution Substances 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229920001531 copovidone Polymers 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000008180 pharmaceutical surfactant Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161581146P | 2011-12-29 | 2011-12-29 | |
| US61/581,146 | 2011-12-29 | ||
| US201261645696P | 2012-05-11 | 2012-05-11 | |
| US61/645,696 | 2012-05-11 | ||
| PCT/US2012/070349 WO2013101550A1 (en) | 2011-12-29 | 2012-12-18 | Solid compositions comprising an hcv inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015140513A Division JP2015227352A (ja) | 2011-12-29 | 2015-07-14 | Ｈｃｖ阻害剤を含む固体組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503560A JP2015503560A (ja) | 2015-02-02 |
| JP2015503560A5 true JP2015503560A5 (cg-RX-API-DMAC7.html) | 2015-03-12 |
| JP5781706B2 JP5781706B2 (ja) | 2015-09-24 |
Family
ID=47470243
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014550335A Active JP5781706B2 (ja) | 2011-12-29 | 2012-12-18 | Ｈｃｖ阻害剤を含む固体組成物 |
| JP2015140513A Pending JP2015227352A (ja) | 2011-12-29 | 2015-07-14 | Ｈｃｖ阻害剤を含む固体組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015140513A Pending JP2015227352A (ja) | 2011-12-29 | 2015-07-14 | Ｈｃｖ阻害剤を含む固体組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20130172239A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2797586A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5781706B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104010631B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2857339C (cg-RX-API-DMAC7.html) |
| DE (1) | DE212012000197U1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1201186A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014008008A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013101550A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2840242C (en) | 2011-09-16 | 2019-03-26 | Gilead Sciences, Inc. | Methods for treating hcv |
| KR20210043734A (ko) | 2011-11-16 | 2021-04-21 | 길리애드 파마셋 엘엘씨 | 항바이러스성 화합물로서의 축합된 이미다졸릴이미다졸 |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2015516421A (ja) * | 2012-05-07 | 2015-06-11 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ | １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの経口固形製剤 |
| US8969588B2 (en) * | 2012-06-05 | 2015-03-03 | Gilead Pharmasset Llc | Solid forms of an antiviral compound |
| EP3650013A1 (en) | 2013-01-31 | 2020-05-13 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| TW201446286A (zh) * | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
| CN105358137A (zh) * | 2013-03-15 | 2016-02-24 | 艾其林医药公司 | Sovaprevir片剂 |
| KR20150129005A (ko) | 2013-03-15 | 2015-11-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 무정형 상태의 hcv 억제제의 고체 경구 투여 제형 |
| AU2014250764A1 (en) | 2013-04-12 | 2015-10-29 | Achillion Pharmaceuticals, Inc. | Deuterated nucleoside prodrugs useful for treating HCV |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
| SI3038601T1 (sl) * | 2013-08-27 | 2020-07-31 | Gilead Pharmasset Llc | Formulacija kombinacije dveh protivirusnih spojin |
| EP3102210A4 (en) * | 2014-02-05 | 2017-10-11 | Merck Sharp & Dohme Corp. | Pharmaceutical composition of selective hcv ns3/4a inhibitors |
| CA2937942A1 (en) * | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
| EP3102188A4 (en) * | 2014-02-05 | 2017-07-12 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| JP2017512811A (ja) * | 2014-04-03 | 2017-05-25 | サンド・アクチエンゲゼルシヤフト | 非晶質ソホスブビルを含む固体組成物 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| WO2016038542A2 (en) * | 2014-09-10 | 2016-03-17 | Mylan Laboratories Limited | Polymorphic forms of sofosbuvir |
| WO2016075588A1 (en) * | 2014-11-11 | 2016-05-19 | Sun Pharmaceutical Industries Limited | Stable amorphous daclatasvir dihydrochloride |
| AU2016217952A1 (en) * | 2015-02-13 | 2017-09-28 | Sandoz Ag | Pharmaceutical compositions comprising Ledipasvir and Sofosbuvir |
| WO2016145269A1 (en) | 2015-03-12 | 2016-09-15 | Teva Pharmaceuticals International Gmbh | Solid state forms ledipasvir and processes for preparation of ledipasvir |
| WO2017021904A1 (en) * | 2015-08-03 | 2017-02-09 | Laurus Labs Private Limited | Daclatasvir free base and process for the preparation thereof |
| WO2017023714A1 (en) * | 2015-08-04 | 2017-02-09 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
| WO2017023713A1 (en) * | 2015-08-04 | 2017-02-09 | Merck Sharp & Dohme Corp. | Methods for making pharmaceutical solid dosage forms of spray-dried dispersions |
| US20180228828A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
| US20180228827A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2016336244A1 (en) | 2015-10-07 | 2018-04-12 | Sandoz Ag | Solid pharmaceutical composition comprising amorphous sofosbuvir |
| WO2017072714A1 (en) | 2015-10-30 | 2017-05-04 | Lupin Limited | Stable ledipasvir premix and process of preparation thereof |
| BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
| EP3496705A1 (en) | 2016-08-12 | 2019-06-19 | Sandoz AG | Solid pharmaceutical composition comprising amorphous sofosbuvir |
| WO2018078536A1 (en) | 2016-10-26 | 2018-05-03 | Lupin Limited | Stable solid dispersion of sofosbuvir and process for preparation thereof |
| CN106727516A (zh) * | 2017-01-10 | 2017-05-31 | 山东省立医院 | 一种治疗丙型肝炎的药物组合物 |
| WO2019134971A1 (en) * | 2018-01-04 | 2019-07-11 | Sandoz Ag | Encapsulated particles comprising a pharmaceutically active ingredient |
| US11378965B2 (en) | 2018-11-15 | 2022-07-05 | Toyota Research Institute, Inc. | Systems and methods for controlling a vehicle based on determined complexity of contextual environment |
| CN113209087B (zh) * | 2020-02-05 | 2023-11-07 | 歌礼药业（浙江）有限公司 | 一种抑制冠状病毒的药物组合物及其用途 |
| AU2021391823A1 (en) | 2020-12-03 | 2023-06-29 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| IL307454A (en) | 2021-04-07 | 2023-12-01 | Battelle Memorial Institute | Technologies for rapid design, construction, testing, learning to identify and use non-viral vectors |
| NL2028762B1 (en) * | 2021-07-16 | 2023-01-23 | Seranovo Holding B V | Micelle-generating formulations for enhanced bioavailability |
| KR102842201B1 (ko) * | 2023-09-19 | 2025-08-06 | 한국해양과학기술원 | Lng 추진 선박용 이산화탄소 액화 시스템 및 방법 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100664822B1 (ko) * | 2002-02-01 | 2007-01-04 | 화이자 프로덕츠 인코포레이티드 | 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법 |
| AR049297A1 (es) * | 2004-06-08 | 2006-07-12 | Vertex Pharma | Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion |
| AU2007226983A1 (en) * | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| AR068916A1 (es) * | 2007-10-19 | 2009-12-16 | Abbott Gmbh & Co Kg | Producto de dispersion solida que contiene un compuesto a base de n- aril urea |
| AR072991A1 (es) * | 2008-08-07 | 2010-10-06 | Schering Corp | Formulaciones farmaceuticas de un inhibidor de la enzima proteasa de hcv en una dispersion molecular solida |
| CA2753667C (en) * | 2009-02-27 | 2015-11-17 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Amorphous salt of a macrocyclic inhibitor of hcv |
| KR20180028070A (ko) * | 2009-05-13 | 2018-03-15 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| CN103819459B (zh) * | 2009-06-11 | 2017-05-17 | 艾伯维巴哈马有限公司 | 抗病毒化合物 |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8415374B2 (en) * | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| NZ605440A (en) * | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| TW201446286A (zh) * | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
-
2012
- 2012-12-18 MX MX2014008008A patent/MX2014008008A/es unknown
- 2012-12-18 EP EP12809070.1A patent/EP2797586A1/en not_active Withdrawn
- 2012-12-18 CN CN201280064815.5A patent/CN104010631B/zh active Active
- 2012-12-18 EP EP15156387.1A patent/EP2907505A3/en not_active Withdrawn
- 2012-12-18 CA CA2857339A patent/CA2857339C/en active Active
- 2012-12-18 JP JP2014550335A patent/JP5781706B2/ja active Active
- 2012-12-18 WO PCT/US2012/070349 patent/WO2013101550A1/en not_active Ceased
- 2012-12-18 US US13/717,993 patent/US20130172239A1/en not_active Abandoned
- 2012-12-18 DE DE212012000197.2U patent/DE212012000197U1/de not_active Expired - Lifetime
- 2012-12-18 HK HK15101710.0A patent/HK1201186A1/xx unknown
-
2015
- 2015-07-14 JP JP2015140513A patent/JP2015227352A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503560A5 (cg-RX-API-DMAC7.html) | ||
| ECSP13012382A (es) | Composiciones sólidas | |
| EA201290892A1 (ru) | Твердые композиции | |
| JP2013032389A5 (cg-RX-API-DMAC7.html) | ||
| HK1201186A1 (en) | Solid compositions comprising an hcv inhibitor | |
| JP2013530958A5 (cg-RX-API-DMAC7.html) | ||
| CL2013001120A1 (es) | Una dispersion solida que comprende un agente inductor de apoptosis de formula definida dispersado en una matriz solida que comprende a) al menos un vehiculo polimerico soluble en agua y b) al menos un surfactante; proceso de preparacion; forma de dosificacion oral, util para tratar una enfermedad neoplasica, inmune o autoinmune. | |
| JP2011105738A5 (cg-RX-API-DMAC7.html) | ||
| JP2015513557A5 (cg-RX-API-DMAC7.html) | ||
| JP2011527299A5 (cg-RX-API-DMAC7.html) | ||
| JP2013542247A5 (cg-RX-API-DMAC7.html) | ||
| JP2013542261A5 (cg-RX-API-DMAC7.html) | ||
| WO2010084115A3 (en) | Antiviral agents | |
| CL2007003250A1 (es) | Compuestos derivados de isoquinolina, inhibidores del virus de hepatitis c; composicion farmaceutica; y uso para el tratamiento de una infeccion por vhc. | |
| JP2014523459A5 (cg-RX-API-DMAC7.html) | ||
| JP2011518842A5 (cg-RX-API-DMAC7.html) | ||
| JP2012199532A5 (cg-RX-API-DMAC7.html) | ||
| WO2007101710A8 (en) | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | |
| WO2008098985A3 (en) | Pharmaceutical composition for the treatment of il-8 mediated diseases | |
| EP2749582A4 (en) | FLUOROUS COPOLYMER AND SURFACE MODIFICATOR THEREFOR AS ACTIVE SUBSTANCE | |
| JP2013010936A5 (cg-RX-API-DMAC7.html) | ||
| JP2008517059A5 (cg-RX-API-DMAC7.html) | ||
| JP2014506577A5 (cg-RX-API-DMAC7.html) | ||
| JP2014508179A5 (cg-RX-API-DMAC7.html) | ||
| JP2013094739A5 (cg-RX-API-DMAC7.html) |